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Cholesterol 25-hydroxylase (CH25H) is an interferon (IFN)-stimulated
gene that shows broad antiviral activities against a wide range
of enveloped viruses. Here, using an IFN-stimulated gene screen
against vesicular stomatitis virus (VSV)-SARS-CoV and VSV-SAR-
S-CoV-2 chimeric viruses, we identified CH25H and its enzymatic
product 25-hydroxycholesterol (25HC) as potent inhibitors of
SARS-CoV-2 replication. Internalized 25HC accumulates in the
late endosomes and potentially restricts SARS-CoV-2 spike protein
catalyzed membrane fusion via blockade of cholesterol export.
Our results highlight one of the possible antiviral mechanisms
of 25HC and provide the molecular basis for its therapeutic
development.
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The novel severe acute respiratory syndrome coronavirus-2(SARS-CoV-2), the etiological agent of coronavirus disease-
2019 (COVID-19) (1, 2), has infected millions of people world-
wide and caused hundreds of thousands of deaths. Currently,
there are no Food and Drug Administration-approved vaccines
available. In most instances, treatment is limited to supportive
therapies to help alleviate symptoms. With the concern that mon-
otherapy would rapidly result in the emergence of resistance, there is
a pressing need to identify multiple effective antivirals as counter-
measures before safe and efficacious vaccines are developed and
deployed. Here, we sought to harness the host innate immune re-
sponses to inhibit SARS-CoV-2 replication. Interferons (IFNs) are
a group of small, secreted proteins (3, 4) that potently suppress the
replication of many viruses through the action of hundreds of IFN-
stimulated genes (ISGs) (5). IFN and ISG levels are up-regulated in
SARS-CoV-2–infected cells and lung tissues from COVID-19 pa-
tients (6, 7). Compared to SARS-CoV, SARS-CoV-2 appears to be
more sensitive to the antiviral activities of IFNs (8). SARS-CoV-2
replication is inhibited by IFN treatment in both immortalized and
primary cells (9–11). While direct IFN administration often results
in adverse effects in humans (12, 13), a targeted approach of acti-
vating the antiviral effects of specific ISGs holds promise.
To identify potential ISG effector proteins that act to block
coronavirus (CoV) at the entry or egress stages of the replication
cycle, we utilized replication-competent chimeric vesicular stoma-
titis virus (VSV) eGFP reporter viruses decorated with either full-
length SARS-CoV spike (S) protein or SARS-CoV-2 S in place
of the native glycoprotein (G) (14). We used an HEK293 cell line
that stably expresses plasma membrane-localized mCherry-tagged
human ACE2, the SARS-CoV and SARS-CoV-2 receptor (2,
15–17) (SI Appendix, Fig. S1A). HEK293-hACE2-mCherry cells
supported 100-fold more VSV-SARS-CoV-2 replication than wild-
type HEK293 cells (SI Appendix, Fig. S1 B–D). We recently showed
robust SARS-CoV-2 infection of primary human intestinal enter-
oids (18). By RNA-sequencing of these intestinal enteroid cultures,
we identified the ISGs most highly and commonly induced by type I
IFN (IFN-β) and type III IFN (IFN-λ). We transduced HEK293-
hACE2 stable cells with lentiviruses encoding 57 of these individual
ISGs and tested their ability to suppress VSV-SARS-CoV and
VSV-SARS-CoV-2 replication.
Significance
The novel severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2), the etiological agent of coronavirus disease-
2019 (COVID-19), has swept the world in unprecedented
speed. In a few months, SARS-CoV-2 has infected millions of
people and caused tens of thousands of deaths. There are no
Food and Drug Administration-approved antivirals or vaccines
yet available and clinical treatments are limited to supportive
therapies that help alleviate the symptoms. Thus, there is an
urgent need to identify effective antivirals as countermeasures
before safe and effective vaccines are developed, tested, and
then produced on a large scale. Our approach is to harness the
germline-encoded interferon antiviral response to inhibit
SARS-CoV-2 replication thereby limiting its pathogenicity.
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Ectopic expression of AXIN2, CH25H, EPSTI1, GBP5, IFIH1,
IFN-induced transmembrane protein (IFITM)-2, IFITM3, and
LY6E resulted in a marked reduction (<36%) in the infectivity of
both viruses, indicated by the number of GFP-infected cells
(Fig. 1A and Dataset S1). Among these genes, IFIH1 (which en-
codes MDA5) activates IFN signaling upon ectopic expression
(19). LY6E and IFITMs recently were reported to inhibit
SARS-CoV-2 (20–22) and thus served as positive controls for our
assay. We validated the top candidates in HEK293-hACE2 cells
expressing CH25H, IFITM1, IFITM2, or IFITM3 (SI Appendix,
Fig. S1E). Consistent with our screen results, the expression of
IFITM2 or IFITM3 but not IFITM1 suppressed VSV-SAR-
S-CoV-2 infection, as evident by a reduction in viral mRNA and
protein levels (Fig. 1B and SI Appendix, Fig. S1F). CH25H was
comparable to IFITM2 and blocked virus replication at 18 h
postinfection (hpi) (Fig. 1B).
CH25H encodes cholesterol 25-hydroxylase that catalyzes the
formation of 25-hydroxycholesterol (25HC) from cholesterol
(23). In many cell types, 25HC is further converted to 7-α,
25-dihydroxycholesterol (7-α, 25-diHC), an oxysterol that functions
as a chemoattractant for T cells and B cells (24). 25HC exhibits
broad inhibitory activities against enveloped viruses of different
families (25, 26), including two porcine CoVs (27). Within a single-
cycle of replication (6 hpi), CH25H expression slightly inhibited the
replication of VSV-SARS-CoV and VSV-SARS-CoV-2 viruses, as
detected by measurement of eGFP expression using flow cytometry
(Fig. 1C). CH25H also decreased wild-type VSV replication
(Fig. 1C), as previously reported (28). We interpret the partial re-
duction of eGFP fluorescence intensity in the infected cells as an
indication that CH25H treatment slows down the kinetics of in-
fection. In contrast, rotavirus and adenovirus replication were not
affected (Fig. 1D). Un-like IFIH1, CH25H expression or 25HC
treatment did not induce type I or type III IFN expression (SI
Appendix, Fig. S1G). The replication of a clinical isolate of
SARS-CoV-2 (2019-nCoV/USA-WA1/2020 strain) also was sup-
pressed in HEK293-hACE2 cells expressing CH25H compared to
control plasmid transfection (Fig. 1E).
To examine the physiological relevance of CH25H antiviral
activity, we used CRISPR/Cas9 to edit the endogenous CH25H
locus. CH25H knockout was verified by both Sanger sequencing
and Western blot (SI Appendix, Fig. S1 H and I). Genetic de-
pletion of CH25H expression resulted in a significant increase of
VSV-SARS-CoV-2 replication (Fig. 1F). Taking these data to-
gether, our genetic screen revealed CH25H as a host restriction
factor of SARS-CoV-2 replication.
Next, we tested whether the antiviral activity of CH25H depends
on 25HC synthesis. As compared to the control 7-α, 25-diHC,
pretreatment of HEK293-hACE2 cells with 25HC for 1 h prior to
VSV-SARS-CoV-2 infection recapitulated the suppressive effect of
CH25H overexpression and reduced virus replication (Fig. 2A).
25HC dose-dependently inhibited VSV-SARS-CoV-2 infection in
MA104 cells, with an approximate EC50 of 1.49 μM (with 95%
confidence interval of 1.09 to 2.08 μM) (Fig. 2B). The 50% cytotoxic
concentration (CC50) was calculated to be at 239 μM. Thus, 25HC
had an excellent selectivity index of 160. When plaque assays were
performed in the presence of 25HC, there was a reduction in both
plaque numbers and sizes (SI Appendix, Fig. S2 A and B). Similarly,
wild-type SARS-CoV-2 virus replication was inhibited by 25HC
treatment (Fig. 2C). The infectivity of a lentivirus backbone-based
SARS-CoV-2 pseudovirus also was suppressed by 25HC, suggesting
that the antiviral effect is restricted to early-stage virus replication
(entry, transcription, translation, and so forth). We and others
previously showed that primary human intestinal epithelial cells and
cardiomyocytes are extrapulmonary SARS-CoV-2 target cells (7, 18,
29). Importantly, 25HC inhibited VSV-SARS-CoV-2 replication in
these primary cell culture systems in a dose-dependent manner
(Fig. 2 E and F and SI Appendix, Fig. S2C).
To investigate a potential 25HC-independent antiviral func-
tion of CH25H (30), we generated a CH25H catalytic mutant
(H422Q and H423Q). Using liquid chromatography-mass spec-
trometry (LC-MS), we quantified the secreted and intracellular
levels of 25HC and downstream product 7-α, 25-diHC. At similar
protein levels (SI Appendix, Fig. S2D), mutant CH25H did not
produce 25HC and 7-α, 25-diHC (Fig. 2G and SI Appendix, Fig.
S2E). As expected, mutant CH25H failed to inhibit VSV-SAR-
S-CoV-2 infection like the wild-type protein (Fig. 2H). Collec-
tively, our results suggest the natural product 25HC mediates the
antiviral activity of CH25H and restricts SARS-CoV-2 virus in-
fection.
During SARS-CoV-2 entry into host cells, S protein binding to
ACE2 enables its cleavage by membrane-bound TMPRSS serine
proteases and subsequent fusion of the viral membrane to the host
cell membrane (15, 18, 31). Previous work suggests that trypsin
treatment or TMPRSS2 expression alleviates IFITM-mediated re-
striction of SARS-CoV and HCoV-229E entry (32, 33). Further-
more, TMPRSS2 is abundantly expressed in human nasal and
intestinal epithelial cells (18, 34). Thus, we examined whether the
presence of TMPRSS2 assists VSV-SARS-CoV-2 to overcome ISG
restriction. TMPRSS2 expression enhanced VSV-SARS-CoV and
VSV-SARS-CoV-2 infection at 6 hpi (SI Appendix, Fig. S3A),
compared to control HEK293-hACE2 cells (Fig. 1C). Un-like
IFITM3, CH25H partially retained its antiviral activity and led to
reduced VSV-SARS-CoV-2 replication in TMPRSS2-expressing
cells (Fig. 3A). Similarly, wild-type SARS-CoV-2 replication was
inhibited by CH25H and 25HC in TMPRSS2-expressing cells
(Fig. 3B).
We next examined the effect of 25HC on SARS-CoV S and
SARS-CoV-2 S mediated membrane fusion, since 25HC blocks
cell fusion by Nipah F and VSV G proteins (28), which are class I
and class III viral fusion proteins, respectively (35). We set up an
in vitro cell-to-cell fusion assay based on the expression of S,
eGFP, ACE2, and TMPRSS2 in HEK293 cells, independent of
virus infection (Fig. 3C). CH25H expression substantially re-
duced syncytia formation mediated by SARS-CoV-2 S (Fig. 3C).
Although IFITM2 and IFITM3 inhibited VSV-SARS-CoV-2
replication (Fig. 1 A and B), neither prevented S-mediated fusion
(Fig. 3C), suggesting a distinct mode of antiviral action. Com-
pared to SARS-CoV-2 S, SARS-CoV S induced weaker cell fu-
sion, as recently reported (36), and this process was also blocked
by CH25H expression (Fig. 3C). CH25H also inhibited the syn-
cytia formation induced by Western equine encephalitis virus gly-
coproteins (class II) and VSV-G (class III) but not reovirus FAST
p10 (class IV) fusion protein (Fig. 3D). To mimic the virus–cell
membrane fusion, we cotransfected SARS-CoV-2 S and GFP into
donor cells and mixed at 1:1 ratio with ACE2+TMPRSS2+TdTo-
mato cotransfected target cells. As expected, we observed robust
syncytia formation under mock conditions (SI Appendix, Fig. S3B).
CH25H expression in “recipient” cells almost completely abolished
cell–cell fusion (SI Appendix, Fig. S3B). Exogenous 25HC treatment
phenocopied CH25H expression and blocked SARS-CoV-2
S-mediated syncytia formation (Fig. 3E and SI Appendix, Fig. S3B).
Similar to CH25H, 25HC failed to inhibit reovirus FAST p10-
mediated fusion (SI Appendix, Fig. S3C).
To define the underlying antiviral mechanisms of the IFN-
CH25H-25HC axis further, we investigated whether 25HC acts
on viral or host membranes. Preincubation of VSV-SARS-CoV-
2 with 10 μM of 25HC for 20 min had no effect on infectivity, as
opposed to the pretreatment of host cells (SI Appendix, Fig.
S4A). The timing of 25HC addition suggests it primarily acted at
the entry stage of VSV-SARS-CoV-2 replication (SI Appendix,
Fig. S4B). We examined a series of early events and excluded
possible effects of 25HC on: 1) ACE2 surface levels; 2) S cleavage
by TMPRSS2; 3) lipid raft localization, stained by a fluorophore-
conjugated cholera toxin subunit B; 4) plasma membrane fluidity,
stained by 6-dodecanoyl-2-dimethylamino naphthalene (Laurdan)






















(37); 5) endosomal pH; and 6) its ability to directly bind to
recombinant SARS-CoV-2 S protein (SI Appendix, Fig. S4 C
and D).
Both 23-(Dipyrrometheneboron difluoride)-24-norcholesterol
(TopFluor-cholesterol) and [4-(dipyrrometheneboron difluoride)
butanoyl]-25-hydroxycholesterol (C4 TopFluor-25HC) are chem-
ically fluorescently labeled cholesterol and 25HC derivatives that
have been used to study membrane incorporation and lipid me-
tabolism (38). C4 TopFluor-25HC retained an almost identical

































































































































































































































Fig. 1. ISG screen identifies CH25H as an antiviral host factor that restricts SARS-CoV-2 infection. (A) HEK293-hACE2-mCherry cells were transduced with
lentiviral vectors encoding individual ISGs for 72 h and infected with VSV-SARS-CoV or VSV-SARS-CoV-2 (MOI = 1) for 24 h. The percentage of GFP+ cells were
quantified and plotted. Five ISGs were colored and selected for further analysis. (B) Wild-type (WT) HEK293-hACE2 cells or HEK293-hACE2 cells stably
expressing indicated ISGs were infected with VSV-SARS-CoV-2 (MOI = 1). At 18 hpi, the mRNA level of VSV N was measured by qRT-PCR and normalized to
GAPDH expression. (C) HEK293-hACE2 cells with or without CH25H expression were infected with wild-type VSV, VSV-SARS-CoV, or VSV-SARS-CoV-2 (MOI =
10) for 6 h. Cells were harvested and measured for GFP percentage and intensity by flow cytometry. Numbers indicate the percentage of FITC+ virus-infected
cells within the entire population. (D) HEK293-hACE2 cells with or without CH25H expression were infected with VSV-SARS-CoV, VSV-SARS-CoV-2, rhesus
rotavirus RRV strain, or adenovirus serotype 5 (MOI = 3) for 24 h. The levels of VSV N, rotavirus NSP5, and adenovirus hexon were measured by qRT-PCR and
normalized to GAPDH expression. (E) HEK293-hACE2 cells with or without CH25H expression were infected with a clinical isolate of SARS-CoV-2 (2019-nCoV/
USA-WA1/2020 strain, MOI = 0.5). At 24 hpi, the mRNA level of SARS-CoV-2 N was measured by qRT-PCR and normalized to GAPDH expression. (F) HEK293-
hACE2 cells expressing CH25H were transduced with mock or CH25H CRISPR/Cas9 targeting lentiviruses and infected with VSV-SARS-CoV-2 (MOI = 1). At 24
hpi, the mRNA level of VSV N was measured by qRT-PCR and normalized to GAPDH expression. For all panels except A, experiments were repeated at least
three times with similar results. The experiment in A was performed twice with average numbers indicated on the graph. Raw data are listed in Dataset S1.
Data are represented as mean ± SEM. Statistical significance is from pooled data of the multiple independent experiments (*P ≤ 0.05; **P ≤ 0.01;
***P ≤ 0.001).






























Fig. S4E) and blocked SARS-CoV-2 S-induced syncytia formation
(SI Appendix, Fig. S4F), enabling us to use it as a tool to probe the
antiviral mechanism of 25HC. Upon host cell uptake, C4 TopFluor-
25HC exhibited punctate patterns and partially colocalized with
lysobisphosphatidic acid (LBPA)-positive late endosomes and
LAMP1+ lysosomes but not Rab4+ recycling endosomes (Fig. 4A).
Thus, we hypothesized that SARS-CoV-2 depends on endosomal
trafficking to establish active replication. Consistent with this hy-
pothesis, ectopic expression of Rab5 and Rab7 dominant-negative
mutants but not the wild-type proteins significantly decreased
VSV-SARS-CoV-2 infection (Fig. 4B and SI Appendix, Fig. S4G).
However, Rab5 and Rab7 mutants did not have an additive effect
with 25HC treatment (Fig. 4B), further suggesting that 25HC may
act at these endosomal vesicles.
25HC is capable of binding Niemann-Pick C1 (NPC1)
in vitro (39), which is responsible for the egress of cholesterol
from the endosomal/lysosomal compartment (40). 25HC
treatment led to an accumulation of intracellular TopFluor-
cholesterol (Fig. 4C). We also observed that in cells stained
with filipin, which labels unesterified cholesterol and prefer-
entially recognized cholesterol over 25HC (SI Appendix, Fig.
S5A), a cholesterol accumulation by 25HC and NPC1 inhibitors
itraconazole (ICZ) and U18666A (Fig. 4C). ICZ treatment
significantly reduced VSV-SARS-CoV-2 titers (SI Appendix,
Fig. S5B). The antiviral activity of 25HC and ICZ depended on
cholesterol accumulation in the endosomal/lysosomal compartment
because the inhibition was markedly diminished in serum-free
media that is devoid of cholesterol (SI Appendix, Fig. S5C). Con-




Fig. 2. 25HC inhibits SARS-CoV-2 replication. (A) HEK293-hACE2 cells were treated with 7-α, 25-diHC or 25HC at 0.1, 1, or 10 μM for 1 h and infected with
VSV-SARS-CoV-2 (MOI = 5). GFP signals were detected at 24 hpi. (Scale bars, 200 μm.) (B) MA104 cells were treated with 25HC at 0.3 to 30 μM for 1 h and
infected with VSV-SARS-CoV-2 (MOI = 0.1) for 24 h. GFP signals were captured by Typhoon, quantified by ImageJ, and plotted as percentage of inhibition. For
CC50 measurement, cells were treated with inhibitors at 0.3 μM to 1 mM for 25 h and analyzed by a Cell Counting Kit 8 and BioTek ELx800 Microplate Reader.
(C) HEK293-hACE2 cells were treated with 7-α, 25-diHC or 25HC at 10 μM for 1 h and infected with SARS-CoV-2 (MOI = 0.5). At 24 hpi, the mRNA level of
SARS-CoV-2 N was measured by qRT-PCR and normalized to GAPDH expression. (D) HEK293T cells were transfected with ACE2 and TMPRSS2, treated with
25HC at 10 or 30 μM for 1 h, and infected with SARS-CoV-2-S-lenti-GFP pseudoviruses (1.45 × 104 pg of HIV p24). GFP+ cells were quantified at 24 hpi. (E)
Differentiated human duodenum enteroids in monolayer were treated with 25HC at 10 μM for 1 h and apically infected with VSV-SARS-CoV-2 (MOI = 1). At 24
hpi, the mRNA level of VSV-N was measured by qRT-PCR and normalized to GAPDH expression. (F) Human induced pluripotent stem cell (iPSC)-derived
cardiomyocytes were treated with 25HC at 3 or 10 μM for 1 h and infected with VSV-SARS-CoV-2 (MOI = 0.01). At 96 hpi, the mRNA level of VSV-N was
measured by qRT-PCR and normalized to GAPDH expression. (G) HEK293-hACE2 cells were transfected with wild-type or enzymatic mutant CH25H for 36 h.
Cell pellets and culture supernatants were harvested for 25HC mass spectrometry. (H) HEK293-hACE2 cells were transfected with wild-type or enzymatic
mutant CH25H for 24 h and infected with VSV-SARS-CoV-2 (MOI = 1). At 18 hpi, the mRNA level of VSV-N was measured by qRT-PCR and normalized to
GAPDH expression. For all figures, experiments were repeated at least three times with similar results. Data are represented as mean ± SEM. Statistical
significance is from pooled data of the multiple independent experiments (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001).






















U18666A or genetic depletion of NPC1 by CRISPR/Cas9 po-
tently restricted VSV-SARS-CoV-2 replication (Fig. 4 D and E
and SI Appendix, Fig. S5D). In contrast to chloroquine and
camostat, both of which are antiviral but through different
mechanisms, 25HC, ICZ, or U18666A efficiently reduced
SARS-CoV-2 S-mediated cell–cell fusion (SI Appendix, Fig.
S5E). Finally, all three compounds suppressed the replication
of a recombinant SARS-CoV-2 virus that encodes an mNeon-
Green reporter (41) in Vero E6 cells (Fig. 4F). Collectively,
our data support a model that 25HC suppresses SARS-CoV-2 S
protein-mediated fusion, which inhibits virus replication, possibly
by altering cholesterol levels.
The identification of ISGs against different virus families have
provided invaluable insights into both virus entry pathways and
host innate immune system evolution (42–45). To date, few ISGs
have been identified that restrict SARS-CoV replication [IFITMs
(33) and GILT (46)] and SARS-CoV-2 replication [LY6E (20,
21), IFITMs (21, 22), and ZAP (47)]. Here, we present evidence
that IFN-inducible CH25H and its natural product 25HC restrict
S-mediated membrane fusion and block SARS-CoV-2 entry into
host cells. 25HC has shown broad antiviral activity against a wide
range of enveloped viruses (26, 28, 30, 48) and nonenveloped
viruses, such as reovirus (49) and murine norovirus (50). 25HC
treatment did not inhibit the infectivity of rhesus rotavirus RRV
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Fig. 3. CH25H and 25HC block SARS-CoV-2 S-mediated membrane fusion. (A) Wild-type HEK293-hACE2 cells with or without TMPRSS2 or TMPRSS4 ex-
pression were transfected with mock, IFITM2, IFITM3, or CH25H for 24 h and infected with VSV-SARS-CoV-2 (MOI = 1). At 24 hpi, the mRNA level of VSV N was
measured by qRT-PCR and normalized to GAPDH expression. (B) HEK293-hACE2-TMPRSS2 cells with or without CH25H expression were infected with a clinical
isolate of SARS-CoV-2 (MOI = 0.5). At 24 hpi, the mRNA level of SARS-CoV-2 N was measured by qRT-PCR and normalized to GAPDH expression. (C) HEK293-
hACE2-TMPRSS2 cells were cotransfected with eGFP, either SARS-CoV S or SARS-CoV-2 S, and IFITM2, IFITM3, or CH25H for 24 h. The red arrows highlight the
syncytia formation. Enlarged images of mock condition are highlighted by red boxes and included as Insets (magnification, 160-fold). (Scale bars, 200 μm.) The
number of cells in each GFP+ syncytia was quantified based on the six brightest syncytia per image. (D) HEK293 cells were cotransfected with eGFP, Western
equine encephalomyelitis virus (WEEV) E1 and E2, VSV G, or reovirus FAST p10, with or without CH25H for 24 h. The red arrows highlight the syncytia
formation. Enlarged images of mock condition are highlighted by red boxes and included as Insets (magnification, 160-fold). (Scale bars, 200 μm.) Quanti-
fication of membrane fusion assays was performed by calculating the number of cells in GFP+ syncytia. (E) HEK293-hACE2 cells stably expressing TMPRSS2 or
TMPRSS4 were cotransfected with SARS-CoV-2 S and eGFP with or without 25HC (10 μM) for 24 h. The red arrows highlight the syncytia formation. (Scale bars,
200 μm.) Quantification of membrane fusion assays was performed by calculating the number of cells in GFP+ syncytia. For all figures, experiments were
repeated at least three times with similar results. Data are represented as mean ± SEM. Statistical significance is from pooled data of the multiple inde-
pendent experiments (*P ≤ 0.05; **P ≤ 0.01; n.s., not significant).






























strain (Fig. 1D), in contrast to the inhibition previously seen with
the human rotavirus Wa strain (51), possibly because they differ in
the endosomal compartment from which they exit into the cytosol
(52). There seem to be two modes of inhibitory mechanisms in-
volved. One requires a high micromolar concentration and more
than 6 h of preincubation time to be effective, in the case of reovirus
(49), pseudorabies virus (53), and human papillomavirus-16 (54),
suggesting an indirect metabolic/cellular pathway-mediated mech-
anism, whereas the other—which includes influenza A virus (26),
Lassa fever virus (55), hepatitis C virus (56), and SARS-CoV-2
(Fig. 2)—functions at a low-micromolar/high-nanomolar range.
Combined with the recent report that apilimod, a PIKfyve
kinase inhibitor, effectively inhibits SARS-CoV-2 infection (57),
we confirm that this virus reaches late endosomal compartment
for membrane fusion and access to the cytosol, at least in
ACE2+TMPRSS2− cells. Recently, two independent studies also
reported the anti–SARS-CoV-2 activity of 25HC (58, 59). In the
second study, Wang et al. (59) observed depletion of cholesterol
at the plasma membrane by 25HC treatment, which is consistent
with our findings of SARS-CoV-2 S protein-mediated fusion
blockade (Fig. 3 C and E). Taken together, our data suggest a
unifying model in which 25HC results in a redistribution of
cholesterol and inhibits both endosomal entry and plasma
membrane fusion, which potentially explains the CH25H in-
hibitory activity against wild-type SARS-CoV-2 in both
TMPRSS2− and TMPRSS2+ cells (Fig. 1 C and E and SI Ap-
pendix, Fig. S3 A and B).
One point worth noting is that wild-type VSV is sensitive to
25HC antiviral effect (Fig. 1C), while its entry is not dependent on
NPC1 (60). Therefore, in the case of SARS-CoV-2, it is plausible
that the reduced virus infection in the absence of NPC1 is uncou-
pled from 25HC antiviral mechanism of action. The latter is likely
multifactorial and involves other cholesterol-binding proteins.
Another question that warrants further investigation is
whether 25HC interferes with other steps in the SARS-CoV-2



















































































































































Fig. 4. 25HC inhibits endosomal cholesterol export to block SARS-CoV-2 fusion. (A) HEK293 cells were incubated with C4 TopFluor-25HC (F-25HC, 2 μM) for 1
h, fixed, and stained for recycling endosome (Rab4), late endosome (LBPA), lysosome (LAMP1), and nucleus (blue, DAPI) (magnification, 800-fold). (Scale bars,
30 μm.) Quantification of colocalization was calculated by Volocity. (B) HEK293-hACE2 cells were transfected with wild-type (WT) or dominant-negative (DN)
mutants of Rab5 or Rab7 for 24 h and infected with VSV-SARS-CoV-2 (MOI = 1) with or without 25HC (10 μM). At 24 hpi, the mRNA level of VSV N was
measured by qRT-PCR and normalized to GAPDH expression. (C) HEK293 cells were treated with TopFluor-cholesterol (F-cholesterol, 2 μM) for 1 h (Upper) or
stained with 50 μg/mL filipin for 30 min (Lower) with or without 25HC (10 μM), ICZ (5 μM), or U18666A (5 μM). (Scale bars, 30 μm.) (D) MA104 cells were treated
with U18666A at 0.01 to 30 μM for 1 h and infected with VSV-SARS-CoV-2 (MOI = 0.1) for 24 h. GFP signals were captured by Typhoon, quantified by ImageJ,
and plotted as percentage of inhibition. (E) HEK293-hACE2-TMPRSS2 cells with or without NPC1 expression were infected with VSV-SARS-CoV-2 (MOI = 1). At
24 hpi, the mRNA level of VSV N was measured by qRT-PCR and normalized to GAPDH expression. (F) Vero E6 cells were treated with 25HC, ICZ, or U18666A at
indicated concentrations for 1 h and infected with recombinant SARS-CoV-2-mNeonGreen virus (MOI = 0.5) for 24 h. Cells were fixed and green signals were
scanned with Typhoon and quantified by ImageJ. EC50 values for each compound are provided in the parentheses. For all figures, experiments were repeated
at least three times with similar results. Data are represented as mean ± SEM. Statistical significance is from pooled data of the multiple independent ex-
periments (*P ≤ 0.05; **P ≤ 0.01).






















of infection at early time points, such as 6 hpi (Fig. 1C and SI
Appendix, Figs. S3A and S4A), the antiviral effect is magnified by
24 hpi (Figs. 1 D and E, 2C, and 4F). It will be of interest to
examine whether this reflects an antagonism of viral particle
maturation or the release or infectivity of virus progeny.
Our data instruct potential drug combinations of 25HC in
conjunction with those targeting the cytoplasmic steps of the
SARS-CoV-2 replication cycle, such as its main protease (61, 62)
or polymerase (63). Further in vivo studies in animal models of
SARS-CoV-2 infection and pathogenesis are required to estab-
lish the physiological impact of 25HC-based drugs or compounds
that modulate antiviral activities.
Materials and Methods
Plasmids, Cells, Reagents, and Viruses.
Plasmids. CH25H, IFIH1, IFITM1, IFITM2, IFITM3, and LY6E were cloned into
pLX304 lentiviral vector with a C-terminal V5 tag. Human ACE2 was cloned
into pDEST-mCherry vector with an N-terminal mCherry tag. TMPRSS2 and
TMPRSS4 plasmids were used as previously described (18). Single-guide RNA
against CH25H or NPC1 (SI Appendix, Table S1) was cloned into lenti-
CRISPR_v2 vector (Addgene, #52961). CH25H point mutations were intro-
duced by QuikChange II site-directed mutagenesis (Agilent, #200524) using
primers in SI Appendix, Table S1. GFP-tagged Rab5 and Rab7 constructs were
used as reported previously (64). Codon-optimized SARS-CoV-2 S was a kind
gift from Nevan Krogan at the University of California, San Francisco, CA
(65). pCAGGS-SARS-CoV S was a kind gift of Paul Bates at the University of
Pennsylvania, Philadelphia, PA (66). pMIG-WEEV-IRES-GFP plasmid was
generated by Zhuoming Liu in the S.P.J.W. laboratory at the Washington
University School of Medicine in St. Louis, St. Louis, MO. PM-GFP and VSV-G
plasmids were obtained from Addgene (#21213 and #12259, respectively).
pCAGGS-FAST-p10 from pteropine orthoreovirus was generated in the
Kobayashi laboratory at the Osaka University, Japan (67). pEGFP-N1 and
pCMV-TdTomato were obtained from Clontech.
Cells. Human embryonic kidney cell line HEK293 (CRL-1573) were originally
obtained from American Type Culture Collection (ATCC) and cultured in
complete DMEM. Rhesus kidney epithelial cell lines MA104 cells were cul-
tured in complete M199 medium. HEK293T, Vero cells (CCL81, ATCC), and
Vero E6 cells (CRL-1586, ATCC) were cultured in complete DMEM (Corning).
HEK293-hACE2-mCherry cells were cultured in complete DMEM with G418
addition (500 μg/mL). HEK293-hACE2 cells and HEK293 cells stably expressing
ACE2 and TMPRSS2 were used as previously described (18). For over-
expression, HEK293-hACE2 cells were transduced with lentiviruses encoding
CH25H for 2 d in the presence of polybrene (8 μg/mL) and cultured in DMEM
containing 5 μg/mL of blasticidin. For CRISPR knockout, HEK293-hACE2-
TMPRSS2 cells were transduced with lentiviruses encoding Cas9 and single-
guide RNA against CH25H or NPC1 for 2 d and cultured in the presence of
puromycin (1 μg/mL).
Reagents. 25HC, 7-α, 25-diHC, trypsin, U18666A, and filipin were purchased
from Sigma-Aldrich. C4 TopFluor- 25HC and TopFluor-cholesterol were
purchased from Avanti Polar Lipids. The 6-Dodecanoyl-2-dimethylamino-
naphthalene (Laurdan, D250), cholera toxin subunit B (C34777), and pHrodo
AM Variety Pack (P35380) were purchased from Thermo Fisher. ICZ and
camostat were purchased from Selleck Chemicals. Chloroquine (tlrl-chq) was
purchased from Invivogen. The viability of MA104 cells after drug treatment
was determined using the Cell Counting Kit 8 (ab228554, Abcam).
Viruses. Recombinant VSV-eGFP-SARS-CoV-2 was previously described (14).
VSV-eGFP-SARS-CoV was constructed in a similar manner. Adenovirus (se-
rotype 5) and rotavirus (rhesus RRV strain) were propagated and used as
previously described (68). A clinical isolate of SARS-CoV-2 (2019-nCoV/USA-
WA1/2020 strain) was obtained from Natalie Thornburg at the Centers for
Disease Control and Prevention, Atlanta, GA. An mNeonGreen SARS-CoV-2
reporter virus was used as previously reported (41). SARS-CoV-2 viruses were
passaged in Vero CCL81 cells and titrated by focus-forming assay on Vero E6
cells. Plaque assays were performed in MA104 cells seeded in six-well plates
using an adapted version of the rotavirus plaque assay protocol (69). The
plaque plates were scanned by Amersham Typhoon 5 (GE) and diameters
were measured by ImageJ (NIH).
Identification and Quantification of Oxysterols. Oxysterols were extracted from
pellets (3 × 106 cells) by adding 1 mL of absolute ethanol containing 20 ng of
[2H7]24R/S-hydroxycholesterol, 20 ng [
2H7]22S-hydroxycholest-4-en-3-one (con-
verted from [2H7]22S-hydroxycholesterol by cholesterol oxidase) and 400 ng of
[2H7]cholesterol (all sterols from Avanti Polar Lipids) with sonication in an
ultrasonic bath (5 min). The solution was diluted to give 1.5 mL of 70% ethanol.
To extract secreted oxysterols from the culture medium, medium (1 mL) was
added drop-wise, with sonication in an ultrasonic bath (5 min), to 2.3 mL of
absolute ethanol containing the same amount of internal standards, as above, to
give a solution of 3.3 mL of 70% ethanol. The oxysterols were then separated
from cholesterol, derivatized with Girard P reagent and analyzed by LC-MS(MSn)
on a Orbitrap Elite, as described previously (70). Identification was performed by
comparing retention time, exact mass, and MSn spectra to authentic standards
and quantification was performed by stable isotope dilution using reconstructed
ion-chromatograms generated in the Orbitrap.
Cardiomyocyte Infection. Human induced pluripotent stem cell-derived car-
diomyocytes (R1117) were purchased from Cellular Dynamics International
and seeded onto a 24-well plate coated with 0.1% gelatin (07903, Stemcell
Technologies) at 1.36 × 105 cells per well, following manufacturer’s recom-
mendations. The cells were seeded in culture (37 °C, 5% CO2) for 48 h in
plating medium and then changed to maintenance media, which was
replaced every 2 d. VSV-SARS-CoV-2 infections were performed at day 6
after cell seeding.
SARS-CoV-2-Lenti-GFP Pseudovirus Preparation. Confluent HEK293T cells in six-
well plates were cotransfected with plasmids pLenti-CMV-GFP-Puro (Addg-
ene #17448) (71), psPAX2 (Addgene #12260), and pcDNA3.1-SARS-CoV-2-
spike (Addgene #145032) (72) with a mass ratio of 4:3:1 (1.6 μg, 1.2 μg, and
0.4 μg, respectively) by Lipofectamine 3000 (Life Technologies). The super-
natant was collected at days 2, 3, and 4 posttransfection and combined. To
concentrate the pseudovirus particles from the collected supernatant,
polyethylene glycol (PEG)-8000 powder was added to a final concentration
(wt/vol) of 10% and the mixture was gently rotated at 4 °C overnight, fol-
lowed by centrifugation at 1,000 × g for 30 min at 4 °C. The pellet was
dissolved in serum-free DMEM/F12 medium with 1% volume of the original
supernatant samples. The concentrated virus stock was aliquoted and stored
at −80 °C. For HIV-1 p24 titration assay, the concentrated pseudovirus par-
ticles were diluted in PBS (or DMEM/F12 medium) by 10,000-fold and sub-
jected to the titration assay by using HIV-1 p24 quantitation ELISA Kit
(Abcam) according to the manufacturer’s directions.
RNA Extraction and Quantitative PCR. Total RNAwas extracted from cells using
RNeasy Mini kit (Qiagen) and reverse transcription was performed with High
Capacity RT kit and random hexamers, as previously described (73). Quan-
titative PCR was performed using the AriaMX (Agilent) with a 25-μL reaction,
composed of 50 ng of cDNA, 12.5 μL of Power SYBR Green master mix or
Taqman master mix (Applied Biosystems), and 200 nM both forward and
reverse primers. All SYBR Green primers and Taqman probes used in this
study are listed in SI Appendix, Table S1.
Flow Cytometry. HEK293-hACE2 or HEK293-hACE2-TMPRSS2 cells with or
without CH25H expression were inoculated with wild-type VSV-GFP,
VSV-SARS-CoV, or VSV-SARS-CoV-2 at a multiplicity of infection (MOI) = 10
(based on titers in Vero cells) for 1 h at 37 °C. At 6 hpi, cells were harvested
and fixed in 4% PFA. GFP+ cells were determined by BD LSRFortessa X-20 cell
analyzer and analyzed by FlowJo v10.6.2 (BD).
Brightfield and Immunofluorescence Microscopy. For brightfield and epi-
fluorescence, cultured cells were imaged by REVOLVE4 microscope (ECHO)
with a 10× objective. For confocal microscopy, samples in eight-well chamber
slides were fixed in 4% paraformaldehyde for 10 min at room temperature
and stained as previously described (74). Cells were permeabilized and
stained with antibodies against DAPI (P36962, Thermo Fisher), LAMP1
(9091S, Cell Signaling), LBPA (MABT837, Sigma), and Rab4 (ab13252, Abcam)
at room temperature for 1 h. For filipin staining, cells were fixed and incu-
bated with 50 μg/mL filipin (SAE0087, Sigma-Aldrich) at 37 °C for 30 min.
Stained cells were washed with PBS, whole-mounted with Antifade
Mountant, and imaged with a Zeiss LSM880 Confocal Microscope at the
Molecular Microbiology imaging core facility at Washington University in St.
Louis. Images were visualized by Volocity v6.3 and quantification was de-
termined by ImageJ (NIH).
Western Blotting. Cell lysates were harvest in RIPA buffer supplemented with
protease inhibitor mixture and phosphatase inhibitor. Proteins were resolved
in SDS/PAGE and analyzed by antibody as described previously (75) using the
following antibodies and dilutions: ACE2 (MAB933, R&D Systems), GAPDH
(631402, BioLegend), GFP (2555S, Cell Signaling), NPC1 (ab124801, Abcam),
SARS-CoV-2 S1 (40590-T62, Sino Biological), SARS-CoV-2 S2 (40592-T62, Sino






























Biological), and V5 (13202S, Cell Signaling). Secondary antibodies were anti-
rabbit (7074, Cell Signaling) or anti-mouse (7076, Cell Signaling) IgG horse-
radish peroxidase-linked antibodies. Protein bands were visualized with
Clarity ECL substrate and a Bio-Rad Gel Doc XR system.
Statistical Analysis. All bar graphs were displayed as means ± SEM. Statistical
significance in the data in Figs. 1 E and F, 2C, 3B, and 4E and SI Appendix,
Figs. S1 C and D, S2B, and S5B was calculated by Student’s t test using Prism
8.4.2 (GraphPad). Statistical significance in the data in Figs. 1 B and D, 2 D,
F–H, 3 C–E, and 4 A and B and SI Appendix, Figs. S1G, S2E, S3 B and C, S4A,
and S5E was calculated by pairwise ANOVA using Prism 8. Nonlinear re-
gression (curve fit) was performed to calculate EC50 and CC50 values for Figs.
2B and 4 D and F and SI Appendix, Fig. S4E. All data are presented as *P ≤
0.05, **P ≤ 0.01, and ***P ≤ 0.001. All experiments other than Fig. 1A were
repeated at least three times. Fig. 1A was performed twice with average
numbers indicated on the graph. The raw data are included in Dataset S1.
Data Availability. All study data are included in the article and supporting
information.
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